At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.
Close
MRNY YieldMax MRNA Option Income Strategy ETF
Market Closed 05-22 16:00:00 EDT
15.46
-0.03
-0.19%
盘后15.71
+0.25+1.62%
19:55 EDT
High15.74Low15.35Vol101.88K
Open15.63D1 Closing15.49Amplitude2.48%
Mkt Cap82.40MTradable Cap82.40MTotal Shares5.33M
T/O1.58MT/O Rate1.91%Tradable Shares5.33M
P/B--ROE--EPS0.00
52wk High--52wk Low--P/E--
Dividend--Div.Yield--ROA--

Loading ...

Moderna director Noubar Afeyan reports disposal of 9,263 shares for $433,469.92
Reuters  ·  07:00
Moderna director Noubar Afeyan reports disposal of 9,263 shares for $433,469.92
Moderna, Merck cancer combo cuts melanoma spread risk at five years
Reuters  ·  05-22 05:00
Moderna, Merck cancer combo cuts melanoma spread risk at five years
Sector Update: Healthcare Stocks Rise Thursday Afternoon
MT Newswires Live  ·  05-22 01:55
Sector Update: Healthcare Stocks Rise Thursday Afternoon
Mixed options sentiment in Moderna with shares down 1.67%
TIPRANKS  ·  05-22 00:11
Mixed options sentiment in Moderna with shares down 1.67%
BUZZ-U.S. STOCKS ON THE MOVE- Intuit, Deere, Advance Auto Parts
Reuters  ·  05-21 23:53
BUZZ-U.S. STOCKS ON THE MOVE- Intuit, Deere, Advance Auto Parts
Market Chatter: Moderna's Experimental Flu Shot to Be Reviewed by FDA Panel in June
MT Newswires Live  ·  05-21 23:37
Market Chatter: Moderna's Experimental Flu Shot to Be Reviewed by FDA Panel in June
Moderna's Experimental Flu Shot to be Reviewed by FDA Panel in June, Bloomberg Reports
MT Newswires Live  ·  05-21 23:25
Moderna's Experimental Flu Shot to be Reviewed by FDA Panel in June, Bloomberg Reports
FDA to hold advisory hearing to debate Moderna’s flu vaccine, Bloomberg reports
TIPRANKS  ·  05-21 23:20
FDA to hold advisory hearing to debate Moderna’s flu vaccine, Bloomberg reports
Moderna Shares Down 2.9% After US FDA to Hold Expert Committee Meeting to Review Co's Flu Vaccine
THOMSON REUTERS  ·  05-21 22:46
Moderna Shares Down 2.9% After US FDA to Hold Expert Committee Meeting to Review Co's Flu Vaccine
US FDA to hold expert committee meeting to review Moderna's flu vaccine
Reuters  ·  05-21 22:38
US FDA to hold expert committee meeting to review Moderna's flu vaccine
MEDIA-FDA plans rare advisory hearing to debate Moderna's flu shot - Bloomberg News
Reuters  ·  05-21 22:33
MEDIA-FDA plans rare advisory hearing to debate Moderna's flu shot - Bloomberg News
FACTBOX-Hantavirus vaccines and treatments under development
Reuters  ·  05-21 00:13
FACTBOX-Hantavirus vaccines and treatments under development
Roivant posts unexpected Q4 profit due to Moderna lawsuit settlement gain
Reuters  ·  05-20 19:08
Roivant posts unexpected Q4 profit due to Moderna lawsuit settlement gain
Roivant Q4 swings to profit of $355.7 million; revenue falls to $2.52 million
Reuters  ·  05-20 19:04
Roivant Q4 swings to profit of $355.7 million; revenue falls to $2.52 million
Biotech Investors Are Tuning Out the MAHA Chaos -- Heard on the Street -- WSJ
Dow Jones  ·  05-20 17:30
Biotech Investors Are Tuning Out the MAHA Chaos -- Heard on the Street -- WSJ
Moderna : JP Morgan Resumes Coverage With Underweight Rating; Price Target $40
THOMSON REUTERS  ·  05-20 13:25
Moderna : JP Morgan Resumes Coverage With Underweight Rating; Price Target $40
Moderna Inc. Stock Slides 5.0%, Underperforms Peers
Dow Jones  ·  05-20
Moderna Inc. Stock Slides 5.0%, Underperforms Peers
BUZZ-U.S. STOCKS ON THE MOVE- Hims & Hers Health, Driven Brands, Onto Innovation
Reuters  ·  05-20
BUZZ-U.S. STOCKS ON THE MOVE- Hims & Hers Health, Driven Brands, Onto Innovation
Mixed options sentiment in Moderna with shares down 3.48%
TIPRANKS  ·  05-20
Mixed options sentiment in Moderna with shares down 3.48%
Moderna President Stephen Hoge disposes 53,336 shares worth $2.58 million
Reuters  ·  05-19
Moderna President Stephen Hoge disposes 53,336 shares worth $2.58 million

Introduction

Company Name.
YieldMax MRNA Option Income Strategy ETF
Affiliated Markets:
ARCA
Listing Date:
--
Main Business:
The fund advisor will seek to employ the fund's investment strategy as the fund relates to MRNA regardless of whether there are periods of adverse market, economic, or other conditions and will not seek to take temporary defensive positions during such periods. The fund is non-diversified.
Issue price:
--